

HOSPITAL AUTHORITY DRUG FORMULARY

(v20.5 - w.e.f. 26 Apr 2025)

new drugs listed highlighted in "yellow" color

(1) The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand.

(2) Some drugs may appear in more than one category due to different formulations and/or indications.

(3) The "Special" drugs will be prescribed as clinically indicated based on the specified indications.

(4) Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed in the HA Drug Formulary.

BNF	General Drugs	Special Drugs	Self-financed item With Safety Net	Self-financed item Without Safety Net
	MUSCULOSKELETAL AND JOINT DISEASES			
10	肌肉骨骼和關節疾病藥物			
10.1	DRUGS USED IN RHEUMATIC DISEASES AND GOUT			
	ALLOPURINOL	ADALIMUMAB	ABATACEPT	TOFACITINIB
	COLCHICINE	CELECOXIB	ADALIMUMAB	
	DEPO MEDROL + LIDOCAINE (OR EQUIV)	DICLOFENAC	ANIFROLUMAB	
	DICLOFENAC	ETORICOXIB	BARICITINIB	
	DICLOFENAC (SUPP)	FEBUXOSTAT	BELIMUMAB	
	HYDROXYCHLOROQUINE	LEFLUNOMIDE	CERTOLIZUMAB PEGOL	
	IBUPROFEN	PIROXICAM	ETANERCEPT	
	INDOMETHACIN	RASBURICASE	GOLIMUMAB	
	MEFENAMIC ACID	SULINDAC	GUSELKUMAB	
	METHOTREXATE	TOCILIZUMAB	INFLIXIMAB	
	NAPROXEN		RISANKIZUMAB	
	PENICILLAMINE		RITUXIMAB	
	PROBENECID		SARILUMAB	
	SULPHASALAZINE		SECUKINUMAB	
	TRIAMCINOLONE ACETONIDE		TOCILIZUMAB	
			TOFACITINIB	
			UPADACITINIB	
			USTEKINUMAB	
10.2	DRUGS USED IN NEUROMUSCULAR DISORDERS			
	BACLOFEN	BACLOFEN		
	DIAZEPAM			
	NEOSTIGMINE			
	ORPHENADRINE			
	PHYSOSTIGMINE SALICYLATE			
	PYRIDOSTIGMINE			
	QUININE			
	TOLPERISONE			
10.3	DRUGS FOR THE RELIEF OF SOFT-TISSUE INFLAMMATION			
	METHYL SALICYLATE COMPOUND (TOPICAL)	HYALURONIDASE		DICLOFENAC (TOPICAL)